BGB-A317-306 JapicCTI-194741
Active, not recruiting
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Beigene Study ID 
BGB-A317-306 JapicCTI-194741
ClinicalTrials.gov ID
EudraCT Number
2018-000587-28
Clinical Drug Trials ID
CTR20181013
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL